US Penny Stocks With Market Caps Under $3B

In This Article:

Stocks in the United States have recently taken a breather following a post-election rally, with major indices like the Dow Jones Industrial Average and S&P 500 experiencing slight declines after reaching record highs. Amidst this backdrop, investors continue to explore diverse opportunities across various market segments. Penny stocks, often representing smaller or newer companies, remain a relevant investment area despite their somewhat outdated label. These stocks can offer surprising value when backed by solid financial foundations, presenting potential for significant returns.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

BAB (OTCPK:BABB)

$0.839

$5.67M

★★★★★★

QuantaSing Group (NasdaqGM:QSG)

$3.08

$161.01M

★★★★★★

Data Storage (NasdaqCM:DTST)

$4.94

$33.86M

★★★★★★

RLX Technology (NYSE:RLX)

$1.59

$2.03B

★★★★★★

AsiaFIN Holdings (OTCPK:ASFH)

$1.00

$79.11M

★★★★★★

PHX Minerals (NYSE:PHX)

$3.34

$125.56M

★★★★★☆

So-Young International (NasdaqGM:SY)

$1.25

$86.82M

★★★★☆☆

Flexible Solutions International (NYSEAM:FSI)

$4.35

$54.41M

★★★★★★

LexinFintech Holdings (NasdaqGS:LX)

$3.20

$591.89M

★★★★★★

Zynerba Pharmaceuticals (NasdaqCM:ZYNE)

$1.30

$65.6M

★★★★★☆

Click here to see the full list of 739 stocks from our US Penny Stocks screener.

Let's review some notable picks from our screened stocks.

CollPlant Biotechnologies

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine company specializing in 3D bioprinting of tissues and organs, as well as medical aesthetics, with a market cap of $45.59 million.

Operations: The company generates its revenue from the biotechnology segment, amounting to $0.69 million.

Market Cap: $45.59M

CollPlant Biotechnologies, with a market cap of US$45.59 million, is a pre-revenue company in the regenerative and aesthetic medicine space, generating less than US$1 million in revenue. Despite being unprofitable and not expected to achieve profitability soon, it has a seasoned management team and no debt. Its short-term assets significantly exceed both short- and long-term liabilities. Recent strategic collaborations with Stratasys focus on innovative 3D bioprinting solutions for breast implants, targeting the substantial US$3 billion global breast implant market. The company maintains sufficient cash runway for over three years based on current free cash flow levels.